Every material Form 8-K Bio-Rad Laboratories filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Bio-Rad reported third-quarter 2025 revenue of $653.0 million, up 0.5% from a year earlier but down 1.7% on a currency-neutral basis. A $495.3 million loss from the change in fair market value of its Sartorius AG investment drove a GAAP net loss of $341.9 million, or $12.70 per diluted share, compared with net income of $653.2 million a year earlier. The company kept its full-year 2025 non-GAAP outlook unchanged.
GAAP net loss of $341.9 million, or $12.70 per diluted share, versus net income of $653.2 million, or $23.34 per share, in Q3 2024
Non-GAAP net income of $60.8 million, or $2.26 per diluted share, versus $56.3 million, or $2.02 per share, a year earlier
Non-GAAP operating margin of 11.8% versus 11.3%; currency-neutral sales decreased 1.7%, with lower sales in both Life Science and Clinical Diagnostics
Full-year 2025 outlook maintained: non-GAAP currency-neutral revenue growth of approximately 0 to 1.0% and non-GAAP operating margin of approximately 12.0 to 13.0%
Bio-Rad reported second-quarter 2025 revenue of $651.6 million, up 2.1% from a year earlier. GAAP net income was $317.8 million, or $11.67 per diluted share, compared with a net loss a year earlier, mainly due to a change in the fair market value of its Sartorius AG investment. Non-GAAP net income fell to $71.0 million, or $2.61 per diluted share, from $88.3 million, or $3.11, and the company raised its non-GAAP operating margin outlook for 2025.
Q2 2025 net sales were $651.6 million, up 2.1% from $638.5 million; currency-neutral sales rose 1.0%.
GAAP net income was $317.8 million, or $11.67 per diluted share, versus a net loss of $(2,165.5) million, or $(76.26) per share, in Q2 2024.
Non-GAAP net income was $71.0 million, or $2.61 per diluted share, versus $88.3 million, or $3.11, a year earlier.
For full-year 2025, non-GAAP operating margin is now expected at approximately 12.0% to 13.0%, up from 10.0% to 12.0%; currency-neutral revenue growth is now expected at approximately 0% to 1.0%, versus a prior range of a 1.0% decline to 1.
Bio-Rad Laboratories appointed Rajat Mehta as Executive Vice President, Global Commercial Operations, effective August 4, 2025, succeeding Mike Crowley, who is retiring after a 26-year career with the company. Mehta previously served as Senior Vice President at Labcorp and as Vice President and General Manager at Thermo Fisher Scientific.
Rajat Mehta becomes EVP, Global Commercial Operations, effective August 4, 2025
Mike Crowley, who announced his retirement on January 31, 2025, will no longer be an executive officer and will remain an employee until September 2025 to assist with the transition
Mehta joins from Labcorp, where he was Senior Vice President overseeing commercial operations for the West Division
Bio-Rad reported first-quarter 2025 net sales of $585.4 million, down 4.2% from a year earlier, and GAAP net income of $64.0 million, down from $383.9 million, when large investment gains boosted results. The company also lowered its full-year 2025 outlook, cutting its non-GAAP operating margin estimate to 10.0% to 12.0% from 13.0% to 13.5% and revising revenue growth to a range of a 1.0% decline to 1.5% growth. The lower outlook signals weaker expected profitability and growth for 2025.
Q1 2025 net sales were $585.4 million, down 4.2% from $610.8 million; currency-neutral sales fell 1.5%, led by Life Science.
Q1 2025 GAAP net income was $64.0 million, or $2.29 per diluted share, versus $383.9 million, or $13.45, in Q1 2024; non-GAAP diluted EPS was $2.54 versus $2.30.
Full-year 2025 non-GAAP currency-neutral revenue is now expected to range from a 1.0% decline to 1.5% growth, down from a prior estimate of 1.5% to 3.5% growth.
Estimated full-year 2025 non-GAAP operating margin was cut to 10.0% to 12.0%, from a prior expectation of 13.0% to 13.5%.
Bio-Rad reported fourth-quarter 2024 net sales of $667.5 million, down 2.0%, and income from operations of $58.4 million, down from $95.3 million a year earlier. A $976.5 million loss from changes in the fair market value of equity securities and a loan receivable, which the company said substantially contributed to the result, drove a net loss of $715.8 million, and the company also began a restructuring that it expects to cost $45 million to $50 million. Shareholders also face a pending Stilla Technologies acquisition and 2025 guidance for non-GAAP currency-neutral revenue growth of 1.5% to 3.5%.
Q4 2024 net sales were $667.5 million, down 2.0% from $681.2 million; Life Science segment sales fell 5.5% to $275.0 million.
Q4 2024 net loss was $715.8 million, or $25.57 per diluted share, versus net income of $349.7 million in Q4 2023.
Restructuring plan initiated February 7, 2025, to eliminate about 5% of the workforce, with total costs estimated at $45 million to $50 million, $30 million to $35 million of which is expected in Q1 2025.
Company made a binding offer to buy all equity interests in Stilla Technologies, a French corporation, and expects 2025 non-GAAP operating margin of 13.0% to 13.5%.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bio-Rad Laboratories filing is on SEC EDGAR ↗. 8-K briefs of other companies →